Research graph
References from MRDtarget: A heuristic Gaussian approach for optimizing targeted capture regions to enhance Minimal Residual Disease detection. Local targets link to admitted publications; unresolved targets remain external evidence.
Molecular characterization of minimal residual cancer cells in patients with solid tumors
10.1016/s1389-0344(00)00073-3 · 2001 · External reference
Molecular residual disease and adjuvant trial design in solid tumors
10.1158/1078-0432.ccr-19-0152 · 2019 · External reference
Detection of solid tumor Molecular Residual Disease (MRD) using Circulating Tumor DNA (ctDNA
10.1007/s40291-019-00390-5 · 2019 · External reference
Impact of circulating tumor DNA-based detection of molecular residual disease on the conduct and design of clinical trials for solid tumors
2022 · External reference
Minimal residual disease as a target for liquid biopsy in patients with solid tumours
10.1038/s41571-024-00967-y · 2025 · External reference
Liquid biopsy and minimal residual disease - latest advances and implications for cure
10.1038/s41571-019-0187-3 · 2019 · External reference
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
10.1038/nm.3519 · 2014 · External reference
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
10.1038/nature22364 · 2017 · External reference
Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling-informed personalized monitoring assay
10.3389/fonc.2023.1221718 · 2023 · External reference
Integrated digital error suppression for improved detection of circulating tumor DNA
10.1038/nbt.3520 · 2016 · External reference
Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics
10.1038/s41551-021-00837-3 · 2022 · External reference
Detecting liquid remnants of solid tumors: circulating tumor DNA minimal residual disease
10.1158/2159-8290.cd-21-0634 · 2021 · External reference
Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer
10.1001/jamaoncol.2019.0528 · 2019 · External reference
Unresolved reference
2001 · External reference
Unresolved reference
2006 · External reference
The mahalanobis distance for functional data with applications to classification
10.1080/00401706.2014.902774 · 2015 · External reference
An incipient fault diagnosis methodology using local Mahalanobis distance: detection process based on empirical probability density estimation
10.1016/j.sigpro.2021.108308 · 2022 · External reference
Remaining useful life prediction of the ball screw system based on weighted Mahalanobis distance and an exponential model
10.21595/jve.2018.19099 · 2018 · External reference
PyClone-VI: scalable inference of clonal population structures using whole genome data
10.1186/s12859-020-03919-2 · 2020 · External reference
10.1109/ipdps.2019.00041
10.1109/ipdps.2019.00041 · External reference
Longitudinal undetectable molecular residual disease defines potentially cured population in localized non-small cell lung cancer
10.1158/2159-8290.cd-21-1486 · 2022 · External reference
Dynamic circulating tumor DNA during chemoradiotherapy predicts clinical outcomes for locally advanced non-small cell lung cancer patients
2023 · External reference
Circulating tumor DNA integrating tissue clonality detects minimal residual disease in resectable non-small-cell lung cancer
10.1186/s13045-022-01355-8 · 2022 · External reference
Reference genome and transcriptome informed by the sex chromosome complement of the sample increase ability to detect sex differences in gene expression from RNA-Seq data
10.1186/s13293-020-00312-9 · 2020 · External reference
